Effect of chronic chromium picolinate in animal models of anxiety and memory

Fundamental and Clinical Pharmacology

Volumn 21, Issue 5, 2007, Pages 531-534

  Khanam, Razia ^a   Pillai, K K ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Chromium picolinate; Elevated plus maze; Spontaneous alternation behavior

Indexed keywords

CHROMIUM PICOLINATE; DRINKING WATER;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MALE; MAZE TEST; MEMORY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC TRANSMISSION; STREPTOZOCIN DIABETES; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FEMALE; MALE; MAZE LEARNING; MEMORY DISORDERS; MEMORY, SHORT-TERM; PICOLINIC ACIDS; RATS; RATS, WISTAR; SEROTONIN; STREPTOZOCIN;

EID: 34548645606     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00503.x     Document Type: Article

References (20)

1. Shinde U.A., Goyal R.K. Effect of chromium picolinate on histopathological alterations in STZ and neonatal STZ diabetic rats. J. Cell. Mol. Med. (2003) 3 322 329.
2. Davidson J.R.T., Kurianm A., Kathrynm M.C., McLeod M.N. Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol. Psych. (2003) 53 261 264.
3. Khanam R., Pillai K.K. Effect of chromium picolinate on modified forced swimming test in diabetic and non-diabetic rats: involvement of serotonergic pathways and potassium channels. Basic Clin. Pharmacol. Toxicol. (2006) 98 155 159.
4. McLeod M.N., Gaynes B.N., Golden R.N. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J. Clin. Psychiat. (1999) 60 237 240.
5. Cosway R., Strachan M.W., Dougall A., Frier B.M. Deary I.J. Cognitive function and information processing in type 2 diabetes. Diabetic Med. (2001) 18 803 810.
6. Messier C., Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav. Brain Res. (1996) 75 1 11.
7. Strachan M.W.J., Ewing F.M.E., Deary I.J. Frier B.M. Is Type II diabetes associated with an increased risk of cognitive dysfunction Diabetes Care (1997) 20 438 445.
8. Biessels G.J., Kamal A., Urban I.J.A., Sprujit B.M., Krkelens D.W., Gispen W.H. Water maze learning and hippocampal synaptic plasticity in streptozotocin diabetic rats: effects of insulin treatment. Brain Res. (1998) 800 125 135.
9. Klein J.P., Waxman P.G. The brain in diabetes: molecular changes in neurons and their implications for end organ damage. Neurology (2003) 2 548 554.
10. Popkin M.K., Callies A.L., Lentz R.D., Colon E.A., Sutherland D.E. Prevalence of major depression, simple phobia, and other psychiatric disorders in patients with long-standing type I diabetes mellitus. Arch. Gen. Psychiat. (1988) 45 64 68.
11. Lustman P.J., Carney R.M., Santiago J.V., Cryer P.E. Stress and diabetic control. Lancet (1983) 1 588 590.
12. Ragozzino M.E., Pal S.N., Unick K., Stefani M.R., Gold P.E. Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injection. J. Neurosci. (1998) 18 1595 1601.
13. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm enteries in an elevated plus maze as a measure of anxiety in the rat. J. Neurosci. Methods (1985) 14 149 167.
14. Steckler T., Sahgal A. The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. Behav. Brain Res. (1995) 67 165 199.
15. Pershad singh H.A., Heneka M.T., Saini R., Amin N.M., Broeske D.J. Feinstein D.L. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J. Neuroinflamm. (2004) 1 3 6.
16. Finn D.A., Rutledge-Gorman M.T., Crabbe J.C. Genetic animal models of anxiety. Neurogenetics (2003) 4 109 135.
17. Lesch K.P., Zeng Y., Reif A., Gutknecht L. Anxiety-related traits in mice with modified genes of the serotonergic pathway. Eur. J. Pharmacol. (2003) 480 185 204.
18. A/ benzodiazepine chloride ionophore receptor complex in the 5,7-DHT Induced anticonflict effects. Life Sci. (1991) 49 139 153.
19. Graeff F.G. Role of 5-HT in defensive behavior and anxiety. Rev. Neurosci. (1993) 4 181 211.
20. 2A receptors. Psychopharmacology (2002) 159 432 436.